The company is attending the 2023 China (Handan) Swine Industry Development Summit.

Mar 21,2023


From March 17 to 18, the 2023 China (Handan) Swine Industry Development Summit was held as scheduled in Handan, and Shengbo Bio made a remarkable appearance at the expo.

Leaders from various departments have visited the company’s booth.

 

During the exhibition, leaders including Director Wang Zhenlai and Deputy Director Han Qing'an from the Hebei Provincial Center for Disease Control and Prevention, Director Wu Ruishuan from the Shijiazhuang City Center for Disease Control and Prevention, and Secretary-General Hua Shipeng from the Pig Raising Association visited the company’s booth and gave high praise and strong support to the company’s work.

Our company’s products—including the African Swine Fever Virus qPCR Detection Kit, the Brucella Vaccine Strain and Wild-Type Strain Dual qPCR Detection Kit, the Classical Swine Fever Virus ELISA Antibody Detection Kit, the Brucella ELISA Antibody Detection Kit, the Porcine Pseudorabies Virus gB ELISA Antibody Detection Kit, and the Porcine Pseudorabies Virus gE ELISA Antibody Detection Kit—have attracted considerable attention from customers. Various colloidal gold test cards are also highly popular due to their ease of use and rapid detection capabilities.

The third-party veterinary laboratory of Shijiazhuang Shengbo Biotechnology Co., Ltd. offers specialized third-party testing and antibody monitoring services for animal diseases such as African swine fever, brucellosis, and foot-and-mouth disease, attracting numerous clients who come to discuss business opportunities.

At the booth, a steady stream of customers came to inquire about products and discuss business matters.


Hot News

Good news: Shengbo Bio and Sheng'ao Bio have both been approved for the Doctoral Innovation Station Construction Project!

Shengbo Bio and Sheng'ao Bio have both been recognized as recipients of the Doctoral Innovation Station Construction Project. This recognition is of great significance for enterprises in enhancing their innovation capabilities, optimizing their talent structure, and accelerating the commercialization of research findings.